Edition:
United States

ARIAD Pharmaceuticals Inc (ARIA.OQ)

ARIA.OQ on NASDAQ Stock Exchange Global Select Market

23.75USD
20 Jan 2017
Change (% chg)

$0.05 (+0.21%)
Prev Close
$23.70
Open
$23.73
Day's High
$23.79
Day's Low
$23.72
Volume
1,083,670
Avg. Vol
1,624,887
52-wk High
$23.81
52-wk Low
$4.38

ARIA.OQ

Chart for ARIA.OQ

About

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $4,612.27
Shares Outstanding(Mil.): 194.20
Dividend: --
Yield (%): --

Financials

  ARIA.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -0.18 -- --
ROI: -6.17 -1.38 14.86
ROE: -- -1.07 16.28

Deals of the day-Mergers and acquisitions

Jan 10 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

Jan 10 2017

BRIEF-Ariad Pharma says termination fee for Takeda deal will be $169 mln

* If deal is terminated by co, to enter definitive agreement with respect to superior proposal, co to pay termination fee of $169 million Source text - http://bit.ly/2ido9QF Further company coverage:

Jan 10 2017

Deals of the day-Mergers and acquisitions

Jan 10 The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Tuesday:

Jan 10 2017

Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal

TOKYO Japan's Takeda Pharmaceutical Co flagged its appetite for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals in a $5.20 billion deal.

Jan 10 2017

UPDATE 2-Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal

* Takeda able to limit debt, retain credit rating post Ariad deal-CFO

Jan 10 2017

Japan's Takeda expects annual sales of Ariad's lung cancer drug to exceed $1 bln

TOKYO, Jan 10 Japan's Takeda Pharmaceutical Co Ltd expects annual sales from new lung cancer drug brigatinib, added to its portfolio with the acquisition of Ariad Pharmaceuticals Inc, will exceed $1 billion, the Japanese company's CEO said on Tuesday.

Jan 09 2017

US STOCKS-Banks, oil stocks hinder Dow's pursuit of 20,000

* Health sector gains on string of multi-billion dollar deals

Jan 09 2017

Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal

Japan's Takeda Pharmaceutical Co Ltd said it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline.

Jan 09 2017

UPDATE 3-Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 bln deal

Jan 9 Japan's Takeda Pharmaceutical Co Ltd said it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline.

Jan 09 2017

BRIEF-Takeda to acquire Ariad Pharmaceuticals

* Ariad Pharmaceuticals Inc - Deal for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion

Jan 09 2017

Earnings vs. Estimates